There are currently 1113 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502
Recruiting
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
12/12/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Schizophrenia
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Spastic Paraplegia - Centers of Excellence Research Network
NCT06553976
Recruiting
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/10/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary
Register for Updates
Donor-Derived Viral Specific T-cells (VSTs)
NCT02048332
Recruiting
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant. A viral specific T cell is a T lymphocyte (a type of white blood cell) that kills cells that are infected (particularly with viruses). Allogeneic means the stem cells come from another person. These VSTs are cells specially designed to fight the virus infections that can happen after a bone marrow tra... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
12/09/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio +1 locations
Conditions: Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
Register for Updates
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
NCT02143830
Recruiting
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Gender:
ALL
Ages:
3 months and above
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Register for Updates
Third Party Viral Specific T-cells (VSTs)
NCT02532452
Recruiting
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
Gender:
ALL
Ages:
2 days and above
Trial Updated:
12/09/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio +1 locations
Conditions: Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Register for Updates
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
NCT03175471
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastogr... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Register for Updates
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
NCT03178630
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection o... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05020535
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Intracerebral Hemorrhage
Register for Updates
INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
NCT05277272
Recruiting
The purpose of this observational study is to collect data on the natural history of disease of patients with Hemophagocytic Lymphohistiocytosis (HLH) including diagnosis, treatments, responses, and outcomes.
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hemophagocytic Lymphohistiocytoses
Register for Updates
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
NCT05556642
Recruiting
There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with rrHBL, prospectively. Cases are identified through: 1. Existing clinical and/or ca... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Relapsed Hepatoblastoma, Refractory Hepatoblastoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Solid Tumor
Register for Updates